Why Cardiff Oncology, Inc.’s (CRDF) Stock Is Up 6.17%
As of Tuesday, November 17, Cardiff Oncology, Inc.’s CRDF share price has surged by 6.17%, which has investors questioning if this is right time to sell.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Rosalio Madrigal
Jenna Brashear
Michael Rose
Michael Rose
| Share Statistics | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $69.4 | $212.8 | 20% |
|
| Shares Out (Mil) | 76.2 | 55.2 | 56% |
|
| Institutional Ownership | 88.2% | 93.3% | 55% |
|
| Float (Mil) | 75.4 | 40.8 | 55% |
|
| Beta | 1.56 | 1.03 | 84% |
|
| Avg Daily Volume (000s) | 3,119 | 559 | 87% |
|
| Price Change (52-week) |
(56.3%) | 40.3% | 18% |
|
| Growth | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.4% | 13.6% | 52% |
|
| Net Income (5yr) | (18.9%) | (10.5%) | 21% |
|
| EPS (5yr) | 8.7% | 15.4% | 45 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.9%) | (15.7%) | 46% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 4 | |
| Current EPS | ($0.123) | ($0.553) | ($0.513) | |
| Month Ago EPS | ($0.140) | ($0.563) | ($0.535) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.133) | ($0.554) | ($0.585) | |
| Year/Year Chg | 6.0% | (19.4%) | 14.4% | |
| Financials | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1 | $40 | 1% |
|
| Net Income (TTM) (Mil) | ($38) | ($44) | 18% |
|
| EPS (TTM) | ($0.537) | ($1.400) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($40) | ($34) | 11% |
|
| Net Cash Flow (TTM) (Mil) | $2 | $-0 | 50% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $32 | $142 | 15% |
|
| Valuation | CRDF | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.48 | 1.97 | 64% |
|
| P/E | na | 16.8 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | CRDF | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 67.6% | 96% |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (75.2%) | (47.4%) | 7% |
|
| ROE | (97.9%) | (51.4%) | 9% |
|
| Liabilities to Assets | 22.8% | 29.6% | 15% |
|
| F-Score | 3 | 3 | 18% |
|
Cardiff Oncology, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors